Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
Launched by ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER, PHOENIX · Apr 15, 2013
Trial Information
Current as of May 01, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male/female 55 to 90 years, inclusive.
- • Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable AD.
- • Modified Hachinski Ischemia Scale score of ≤4.
- • Folstein Mini Mental State Exam score 16-26 at Visit 1.
- • Geriatric Depression Scale score ≤6. For patient with history of depression, he/she have been on steady dose of anti-depressant for at least 3 months.
- • Clinical history and relevant symptoms of Pseudobulbar Affect.
- • Center for Neurologic Study-Lability Scale score at baseline ≥13.
- • Stable hematologic, hepatic, and renal function, with no clinically significant symptoms, and with clinical laboratory results (CBC, clinical chemistry, and urinalysis) up to 1-fold higher than upper limit of normal range.
- • Resting respiratory rate 12-20/minute.
- • MRI or CT scan within past 12 months; no findings inconsistent with diagnosis of AD.
- • ECG (within 4 weeks prior to entry)with no evidence of clinically significant abnormalities.
- • Concurrent treatment with an acetylcholinesterase inhibitor or memantine allowed; must be on stable dose at least 2 months before screening. Dosing must remain stable throughout the study.
- • Use of SSRI's allowed. Must have used for 3 months prior to study entry; dose must remain unchanged during course of study.
- • No current symptoms of depressive disorder.
- • Score of 19 or lower in the Beck Depression Inventory.
- • Agrees to use no prohibited medications during study.
- Exclusion Criteria:
- • Has current serious or unstable illnesses that, in investigator's opinion, could interfere with analysis of safety and efficacy data; has life expectancy \<2 years.
- • No reliable caregiver in frequent contact with patient (at least 10 hours/week.
- • Current or prior history of major psychiatric disturbance.
- • Have been in other clinical study within 30 days of entry.
- • Score of 20 or higher in Beck Depression Inventory.
- • Multiple episodes of head trauma, history within last year of serious infectious disease affecting the brain, head trauma resulting in protracted loss of consciousness, or myasthenia gravis.
- • Within the last 5 years, history of a primary or recurrent malignant disease.
- • Known sensitivity to quinidine or dextromethorphan.
- • History of human immunodeficiency virus, multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions.
- • History of chronic alcohol or drug abuse/dependence within the past 5 years.
- • Judged by investigator to be at serious risk for suicide.
- • Has a recent or current lab result indicating clinically significant lab abnormality.
- • At Visit 1 has ALT/SGPT values ≥2 times upper limit of normal (ULN); AST/SGOT values ≥3 times the ULN; total bilirubin values ≥2 times the ULN.
- • Resting diurnal oxygen saturation \<95%.
- • Received dextromethorphan and quinidine within previous 6 months.
- • Hypotension (systolic BP \<100 mm Hg); postural syncope; unexplained syncope.
- • Used medications that affect the CNS (except for AD) for less than 4 weeks.
- • On disallowed concomitant medications.
- • Experiencing acute exacerbation of underlying neurological disorder within previous 2 months.
About St. Joseph's Hospital And Medical Center, Phoenix
St. Joseph's Hospital and Medical Center, located in Phoenix, Arizona, is a leading healthcare institution dedicated to providing high-quality patient care and advancing medical research. As a prominent clinical trial sponsor, the hospital is committed to exploring innovative treatments and therapies that enhance patient outcomes. With a focus on ethical research practices and collaboration with multidisciplinary teams, St. Joseph’s is at the forefront of clinical trials that address a wide range of medical conditions, ensuring rigorous scientific standards while prioritizing patient safety and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Phoenix, Arizona, United States
Patients applied
Trial Officials
Jiong Shi, MD, PhD
Principal Investigator
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix AZ
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials